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Abstract
Background: Studies of gene regulation often utilize genome-wide predictions of transcription factor (TF) binding
sites. Most existing prediction methods are based on sequence information alone, ignoring biological contexts such
as developmental stages and tissue types. Experimental methods to study in vivo binding, including ChIP-chip and
ChIP-seq, can only study one transcription factor in a single cell type and under a specific condition in each
experiment, and therefore cannot scale to determine the full set of regulatory interactions in mammalian
transcriptional regulatory networks.
Results: We developed a new computational approach, PIPES, for predicting tissue-specific TF binding. PIPES
integrates in vitro protein binding microarrays (PBMs), sequence conservation and tissue-specific epigenetic (DNase I
hypersensitivity) information. We demonstrate that PIPES improves over existing methods on distinguishing between
in vivo bound and unbound sequences using ChIP-seq data for 11 mouse TFs. In addition, our predictions are in good
agreement with current knowledge of tissue-specific TF regulation.
Conclusions: We provide a systematic map of computationally predicted tissue-specific binding targets for 284
mouse TFs across 55 tissue/cell types. Such comprehensive resource is useful for researchers studying gene regulation.
Background
To reconstruct and model transcriptional regulatory
networks (TRNs) we need to know the genome-wide
binding sites of transcription factors (TFs) [1,2]. Chro-
matin immunoprecipitation(ChIP) followed by microar-
ray (ChIP-chip) [3] or sequencing (ChIP-seq) [4] has been
extensively used to study the in vivo binding locations of
individual transcription factors and cofactors in a wide
range of species and tissues [1,2,5-9]. Despite their pop-
ularity, such methods can only study a single TF in a
single cell type, under a specific condition, in each exper-
iment. Thus, it is difficult to use these methods to obtain
a comprehensive understanding of the complicated mam-
malian TRNs. These networks can involve hundreds or
thousands of TFs whose activities change across differ-
ent tissues and conditions. Using computational methods
to integrate other genomic resources in order to predict
tissue-specific transcription factor binding is therefore an
important research challenge.
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Several methods have been developed to use in vitro
data characterizing TF binding specificities to identify TF
binding sites across the genome. Specifically, data from
universal protein binding microarray (PBM) [10,11] is
often used for such analysis. PBM is capable of analyz-
ing the interaction of a sequence-specific TF with tens of
thousands of short DNA sequences (probes) in a single
experiment, and thus provides a highly detailed picture
of TF-DNA interactions. It has been successfully applied
to reveal the binding profiles of hundreds of TFs in yeast
[12], worm [13], mouse [14] and arabidopsis [15]. Some
of the proposed methods for using PBM data repre-
sent TF binding preference by position weight matrices
(PWMs) [11,16,17]. However, PWMs, although popular
due to their simplicity, assume independence between
positions, an assumption which may not hold in many
cases [14,18,19]. In contrast, more sophisticated models
(e.g. using k-mers) may better represent the full binding
profiles of TFs, without loss of information from using
PWM. For instance, it has been suggested that many TFs
have more than one binding preference [14] and these are
easier to represent using k-mers.
© 2013 Zhong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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While in vitro data provides important information
regarding binding specificities, such data is context inde-
pendent. Actual binding is highly dependent on tissue-
specific conditions including chromatin accessibility, the
presence of co-factors, etc [20]. Recently, a number of
studies have reported that epigenetic information includ-
ing certain histone modifications and hypersensitivity to
DNase I cleavage correlate with TF binding in vivo [21,22].
Moreover, functional TFBSs tend to be under stronger
negative selection, leaving a “phylogenetic footprint” in
the genomic sequences. Several methods for predicting
in vivo TF binding sites have attempted to combine such
information with PWMs to predict global binding prefer-
ences [23-26]. However, as mentioned above, PWM may
not be the best representation of TF binding. As we show,
by using a model that retains the dependence between
positions in the motif we can improve upon methods that
integrate epigenetic and PWM data. In addition, none of
these methods have so far been applied to elucidate the
complete set of targets for TFs across a large number of
tissues.
To predict accurate tissue-specific TFBS, we integrate
multiple types of genomic data. The first part of ourmodel
is a biophysically-motivated k-mer based method for ana-
lyzing PBM data, which allows secondary binding pro-
files and nucleotide dependencies in different positions
of the TF binding sites. Next, we develop a new method,
PIPES (probabilistic integration of PBM, epigenetics and
sequence data), to combine the results from the PBM
model with DNase I hypersensitivity (DHS) data and
evolutionary conservation data to predict tissue-specific
TFBS in vivo. We demonstrate that such an integra-
tive model significantly boosts context specific prediction
results compared with using PBM data alone. We also
show that PIPES improves upon other methods devel-
oped for integrating data to predict TFBS [24,26], in some
cases significantly so. Finally, we created a resource for
tissue-specific TRNs using PBM data for 284 mouse TFs
from UniPROBE [27] and DNase I hypersensitivity data
for 55 mouse tissue/cell types from the mouse ENCODE
project [28]. We predict the activities of TFs across dif-
ferent tissues, and, as we show, many of these predictions
agree with current knowledge regarding tissue-specific
roles of TFs. Our tissue specific activity predictions are
also supported by global analysis of TF expression data.
The comprehensive resource of TF binding sites we built
thus provides a reference map for understanding complex
gene expression patterns.
Results
An overview of our PIPES method is shown in Figure 1.
Our model has two components: the left part of the figure
shows our model for the PBM data, and the right part our
model of epigenetics and conservation data. Starting with
raw fluorescent intensities measured by PBM, we first
infer binding probabilities to each individual k-mer with a
biophysically-motivated model (Figure 1a). This informa-
tion, based on PBM alone, can be used to score a sequence
for potential TFBS (Figure 1b). Next, we use tissue specific
DNase I hypersensitivity data to determine chromatin
accessibility (Figure 1c, d), and combine such information
with sequence conservation and the PBM derived scores
to predict in vivo binding sites (Figure 1e).
K-mer based PBM analysis can accurately infer TF binding
specificities
While a number of methods have been suggested to use
PBM data for predicting TF binding sites (in most cases
using PWMs), we decided to extend k-mer based meth-
ods using a biophysically-motivated model (Figure 1a).
K-mer based methods were shown to achieve the best
performance among several techniques for the analysis
of PBM data [29]. Such methods allow an intuitive rep-
resentation of potential alternative binding motifs and
can account for dependency among positions in a motif.
We use lasso regression with positive constraints to learn
model parameters that represent binding probabilities to
individual k-mers, where k is determined as part of the
learning procedure. This results in a sparse model with
relatively few k-mers having nonzero binding probabil-
ities. On average, the number of k-mers with non-zero
probabilities is 398.4 ± 253.2 across 284 mouse TFs with
PBM data available. The model combines the benefits
of recent PWM-based biophysical methods (for example,
BEEML-PBM [16]) with the ability of PBMs to capture
dependencies between positions in a given motif (see
Methods and Supplementary Methods in Additional file 1
for details).
We illustrate the results of our PBM model using four
TFs including Sox12, Esrra, Klf7 and Pou2f1. Figure 2
presents the PWMs derived from the PBM data for these
TFs by the Seed-and-Wobble algorithm [11] (denoted as
S&W PWMs), PWMs in TRANSFAC [30] for the cor-
responding TFs when available, and all the k-mers esti-
mated by our model that have binding probabilities above
0.5. For S&W PWMs, when a secondary binding prefer-
ence was derived [14], both the primary and secondary
PWMs are shown. As can be seen, our k-mer model does
well for this data. For Sox12, the learned k-mers match
well with both the primary and secondary S&W PWMs
(Figure 2a). For Esrra and Klf7, k-mers matching the
consensus sequences of the primary S&WPWMs, respec-
tively, are predicted to have high binding probabilities
(Figure 2b and c), whereas k-mers matching the secondary
S&W PWMs have lower predicted binding probabilities
ranging from 0.2 to 0.44 (not shown in the figure). In the
case of Pou2f1, none of the inferred top k-mers match
the S&W PWM (Figure 2d). However, many of these





Figure 1 Overview of PIPES. (a, b) Starting with raw PBM data for a TF represented as fluorescence intensities to each individual probes, we first
infer binding probabilities to individual short k-mers, and then a given sequence can be scored by such inferred binding probabilities. (c, d) To
predict in vivo TF binding, we take as input the tissue-specific DNase I hypersensitivity data (tag counts) and convert them to probabilities that
represent chromatin accessibility for each position in the genome at each tissue/cell types. (e) The PBM data, DNase data and other types of data
including sequence conservation are combined using an integrative model. See Methods for details.
top k-mers closely match the consensus sequence of the
TRANSFAC motif for Pou2f1 derived from literature evi-
dence (Figure 2d). Overall, these results support the use
of a biophysically-motivated model: the binding proba-
bilities of k-mers are largely consistent with the results
from independent methods and known motifs from
TRANSFAC.
To test our PBM model, and as a baseline, we next
used the inferred binding probabilities to predict in vivo
TF binding. We collected 11 published mouse ChIP-seq
datasets for which the PBM data for the same TF or
for a TF with a similar DNA-binding domain is available
(Additional file 2). From each ChIP-seq dataset, the top
3000 peaks with highest enrichment are extracted, and the
600bp genomic regions centered on the reported peaks
are used as the positive sequences bound by the TF. Then,
600bp sequences that (1) are upstream of and (2) 300bp
apart from each positive sequence, and (3) do not over-
lap with any other positive sequences, are used as negative
sequences. We also explored two alternative options for
constructing negative sequences, including using size-
matched random promoter sequences and randomly gen-
erated sequences. The choice of negative sequence sets
makes very little difference on the AUC values, so we
will only report the results based on the first nega-
tive set here (see Supplementary Results in Additional
file 1, and Additional file 3 for details). We compared our
PBM model with seven other methods that predict affini-
ties of TF binding to given sequences, and the different
methods are evaluated using areas under the ROC curve
(AUC) as a measure of their abilities to correctly classify
the two sets of sequences (see Methods, Supplementary
Results in Additional file 1 and Figure S1 therein for
details).
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Figure 2 Top inferred k-mer binding probabilities for (a) Sox12, (b) Esrra, (c) Klf7 and (d) Pou2f1. The S&W PWMs and TRANSFAC motifs
(when available) for these four factors are also shown. k-mers are colored according to whether they match the consensus sequences of the primary
S&W PWM (red) or secondary S&W PWM (blue). k-mers matching the TRANSFAC motifs are indicated by a “*” in the front. Only k-mers with
coefficients above 0.5 (normalized so that the maximum is equal to 1) are shown.
The results indicate that the performance of our PBM
method is at least comparable, and in some cases better
than, previous methods. For 4 of the 11 TFs we tested
(Esrrb, Sox2, Oct4 and Crx), our method improved over
all other methods. In all other cases, the AUC of our
method ranks within the top 4 (Supplementary Results in
Additional file 1 and Additional file 1: Figure S1 therein).
Notably, in such cases, none of the other methods con-
sistently achieves the best AUC. The PWM-based and
E-score based methods tend to work well for some cases
(for example, BEEML PWM for Klf7 and Max E-score for
Srf ), but for others their performance is not as good. Over-
all, our PBM model has the highest average AUC over the
11 TFs tested (Supplementary Results in Additional file 1,
and Additional file 4).
To further assess the benefits of using PBM to derive
TF binding specificities, we use two other collections
of PWMs for AUC evaluation. The HOMER PWMs
[31] were derived from ChIP-seq datasets, while the
JASPAR PWMs were from multiple sources (including
ChIP-seq, literature curation and PBM data). Overall, the
results from the JASPAR PWMs are very similar to those
obtained from the Seed and Wobble PWMs, and both
are weaker than our method. The use of HOMER PWMs
lead to better overall performance. However, given that
HOMER trains the PWMs from ChIP-seq data and the
same datasets may be used for evaluation, this is clearly
not a fair comparison. We did notice that for some TFs,
ourmethod outperformsHOMER PWMs (e.g.Max: 0.809
vs 0.757). The full details are shown in Supplementary
Results in Additional file 1 and Additional file 4.
Integratedmodel of PBM and DNase I hypersensitivity data
significantly improves TFBS prediction accuracy
PBM data, although powerful, only measures in vitro
binding. Therefore, even when using sophisticated meth-
ods, the ability to predict in vivo binding based on PBM
data is limited. DNase I hypersensitive (HS) sites are
regions of chromatin that are very sensitive to DNase
I cleavage [32], and previous studies have shown that
such hypersensitivity correlates with TF binding [21,22].
To better predict tissue-specific in vivo binding sites, we
developed PIPES, a probabilistic graphical model for inte-
grating DNase I HS data with PBM data. For windows
containing a 36bp genomic region (“site”), we assume the
chromatin of the site could exist in two states: open or
closed, and that only in the open state the chromatin is
accessible to binding by a TF.We infer the chromatin state
by using a mixture model for the DNase HS data: the open
state should be associated with higher tag densities from
the DNase data, and the closed state with lower densities.
The in vivo occupancy of a site is then estimated as the
probability of binding in vitro estimated using result from
the PBM model multiplied by the probability that the site
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is in an open state inferred from the DNase HS data (see
Methods for a detailed description of PIPES).
Figure 3 presents the AUCs from applying PIPES to pre-
dict in vivoTF binding in the corresponding tissues for the
same 11 TFs studied in the previous section. Compared
with using PBM data alone (black bars), the incorpora-
tion of DNase I HS data in the corresponding tissues
(green bars) improves performance for 10 of the 11 TFs.
Overall, the improvement of AUC from adding DNase
HS data across all TFs is statistically significant (p =
0.0049, one sided Wilcoxon rank-sum test). The biggest
improvements are seen for TFs for which the results when
using only PBM data are relatively poor. For example,
when predicting Srf binding sites in heart, even the best
methods analyzed above achieve an AUC only slightly
better than random (Figure 3). By integrating PBM and
DNase data, the performance of our method is improved
by 46% from 0.539 to 0.787 (Figure 3). Similar improve-
ment is also observed for Oct4 (from 0.532 to 0.847).
As another baseline, we evaluated the AUCs from using
DNase HS data alone. Somewhat surprisingly, this feature
alone seems quite discriminative (Figure 3, red bars; see
also Additional file 4): the mean AUC is 0.822. Neverthe-
less, in 8 out of 11 cases, our model using both DNase and
PBM data improves these baseline results and its mean
AUC is also higher at 0.866. We also point out that in
practice it is not appropriate to use the HS data alone to
predict binding sites for a TF as the predictions would not
be specific to the TF of interest.
In addition to DNase I hypersensitivity data, bona fide
TF binding sites are usually under evolutionary pressure
and therefore more conserved [33,34]. We thus further
extended PIPES to incorporate phastCons scores [35] for
each site (Methods). Performance of the full model that
incorporates PhastCons information is shown in Figure 3
(purple bars). As can be seen, while in some cases adding
the conservation information very slightly improves per-
formance (for example for Srf and Oct4), overall using
conservation data does not lead to a significant improve-
ment in prediction accuracy. When the DNase HS data is
not available, using PhastCons in addition to the PBMdata
provides a slight improvement of the AUCs from using
PBM alone (improving the results for 8 out of 11 TFs,
Additional file 4). The average AUC is increased by 1%,
and for some TFs, the improvement can be quite signifi-
cant (e.g. Srf, AUC changes from 0.539 to 0.592 by adding
PhastCons).
Finally, we compare PIPES with recent methods pro-
posed for integrating DNase andmotif information to pre-
dict TFBS. The first method we compare against, termed
‘Intersection”, was used by Neph et al. [26]. This method
intersects sites that have high-scoring PWMmatches for a
TFwith DNaseHS sites to predict in vivo binding (Supple-
mentary Methods in Additional file 1). We also compare
PIPES with CENTIPEDE [24]. CENTIPEDE uses a prob-
abilistic model to integrate the prior information of puta-
tive sites, such as sequence conservation and matches to
PWMs, with the epigenetic data to predict binding sites.
While probabilistic, CENTIPEDE does, however, rely on
a stringent cutoff for PWM match scores to achieve low
false positive rates.
The results are presented in Figure 3. As can be seen,
the intersection method leads to AUCs that are signifi-
cantly lower than the ones obtained by our method for all
11 TFs (cyan bars, p = 9.77 · 10−4, one sided Wilcoxon
rank-sum test), indicating that strict cutoffs (as opposed
to probabilistic integration) may lead to a high rate of
false negatives. Similarly, using the default settings for
Figure 3 AUCs of different integrative methods for predicting in vivo TF binding. The first four bars are from our k-mer PBM data analysis
method (black), simple baseline using only DNase data (red), or from PIPES (green and purple). Cyan bars: Simple overlapping approach that
overlays PWMmatches with DNase data. Orange bars: CENTIPEDE using S&W PWMs to scan sequences and an odd log score of log2(1000) as cutoff.
See main text and also Additional file 1 for more details.
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CENTIPEDE led to AUC scores that are much lower than
ours (Figure 3, orange bars). To further explore this, we
varied the setting of CENTIPEDE, including using differ-
ent PWMs and a range of cutoffs for defining putative
binding sites, but the results remained the same (See
Supplementary Methods and Results in Additional file 1,
and Additional file 4). The difference in AUCs is highly
significant: p = 4.88 · 10−4 (one sided Wilcoxon rank-
sum test) using the best combination of PWM and cutoff
for CENTIPEDE. These results indicate that our PIPES
model, which relies on k-mer based representation and
avoids strict cutoffs, can improve in vivo predictions of
TFBS.
We performed additional analysis to the integration
model. For these, we replace the binding probabilities
predicted from the k-mer model, with those predicted
when using PWMs. Three different versions of PWMs
were used: the Seed-and-Wobble PWMs and RAP PWMs
learned from the same PBMdata, and the JASPAR PWMs.
In all cases, the AUCs are substantially higher than the
ones from the Intersection method and CENTIPEDE
(below or close to the full PIPES model). These results
indicate that the probabilistic integration step alone is
enough to improve upon priormethods (Additional file 4).
The usefulness of the k-mer based analysis provides addi-
tional advantage, as independently demonstrated in the
earlier section.
Combining PBM and DNase data enables the prediction of
tissue-specific TF activities
The recently released mouse ENCODE project data pro-
vides DNase I hypersensitivity data for more than 50
mouse tissue/cell types (Methods). We set out to com-
bine the PBM data for 284 mouse TFs in UniPROBE with
such DNase data to predict tissue-specific TF targets and
determine tissue-specific TF activities (Methods).
Identifying TFs that are highly active in specific tis-
sues is useful for determining the function of such TFs,
and serves as an initial step for reconstructing the tissue-
specific transcriptional regulatory networks. We predict
how likely a TF is functional in any given tissue/cell
type with an activity score for each TF-tissue pair. Our
hypothesis is that if the TF is active in a tissue, it will
bind a number of target sequences, thus the putative TF
binding sites will be overrepresented in the DNase HS
regions (see Methods for details). A higher activity score
indicates that the TF is more active in the correspond-
ing tissue (the expected value is 1 for non-active TFs).
We use a binomial test to assess the statistical signifi-
cance of the activity scores (see Methods). The complete
results, including activity scores and p-values, are pro-
vided in Additional file 5. In Figure 4a we illustrate these
results by focusing on the activity scores calculated for
4 TFs (Gata3, Pou6f1, Crx and Hnf4a) across 18 repre-
sentative tissue/cell types. Gata3 is known to function in
mouse fetal liver haematopoiesis [36], and its expression
had also been observed in leukemia cells [37]. Our results
are in good agreement with the prior knowledge regard-
ing Gata3’s activity: the top two tissues predicted for
Gata3 are E14.5 liver cells and the adult leukemia cell line.
Similarly the top tissue for Pou6f1 is E14.5 whole brain,
in agreement with its known role in brain development
[38]. Crx is an important TF for regulating photoreceptor
genes in retina [39,40], and our method correctly deter-
mined that its activity score in that tissue is the highest.
Finally, Hnf4a is a well known master regulator of liver-
and kidney-specific genes [41,42], as correctly predicted
by our method. While we only show 18 tissues, for all four
TFs the correct tissues shown in Figure 4a have the highest
scores among all 55 tissues we tested (Additional file 5).
To more globally validate these tissue-specific TF activ-
ities, we compared the correlation between our pre-
dicted TF activity scores and mRNA levels for the same
TFs in the corresponding tissue (measured by qRT-PCR
[43]) . Eight tissues and 222 TFs that are common to
both datasets are used (Additional file 6). Even though the
two types of data (PBM and DNase vs. expression) mea-
sure completely different aspects of cellular activity, we
observe a Pearson correlation coefficient of 0.229, which is
highly statistically significant (p < 10−8, permutation test,
Figure 4b). Since many TFs are only post-transcriptionally
regulated, such a significant correlation provides strong
support to the predictions computed by our method.
Existing literature strongly supports predicted TF activities
in several tissues
To further validate our predictions and investigate their
potentials to lead to new biological insights, we took a
closer look at the TFs predicted to be active in the adult
liver tissue. The top five such predictions are shown in
Table 1A (p < 10−100 for all, binomial test). Besides
Hnf4a discussed above, Rara, Nr2f2, Rxra and Tcf7 are
all known to either regulate liver-specific genes or are
involved in maintaining liver metabolism and homeosta-
sis (Table 1A). The 7th ranked factor Tcf7l2 (activity
score of 1.38) was linked to type 2 diabetes risk in previ-
ous studies using SNP data [44], but the mechanism for
its involvement was unclear. Our result indicates that it
may have a regulatory role in liver metabolism. Indeed,
a very recent study confirms its role in regulating key
liver-specific metabolic genes [45]. Our result also assign
a high liver activity score to Cutl1 (1.36, rank 8/284).
Cutl1 was a known transcriptional repressor of termi-
nal differentiation genes in several cell lineages including
hepatocyte [46]. Recently, Cutl1 was identified as tar-
get of the liver-specific microRNA miR122 and a central
mediator of the effects caused by the deregulation of
miR122 in hepatocellular carcinoma [47]. Further down
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Figure 4 Results for tissue-specificity TF activity prediction. (a) Predicted tissue activity scores for 4 TFs across 18 representative tissue/cell
types. Arrows indicate known functions of the TF in the corresponding tissue as supported by literature evidence. In all cases, the highest activity
score matches a known tissue for the factor. (b) Pearson correlation coefficients between tissue specific expression experiments and the activity
level predicted by our method. The distribution is based on 108 permutations of the activity scores. The value from the real predictions is indicated
by the arrow on the right.
the list, Foxa2 (1.32, rank 10/284) is known to regu-
late lipid metabolism and ketogenesis related genes in
liver [48], and Lef1 (1.31, rank 11/284) is a prognostic
biomarker for liver metastasis in colorectal cancer. Other
TFs ranked within the top 20 for liver include Tcf1 and
Tcf2, members of the T-cell factor (Tcf) family that are
critical for hepatocyte metabolism and function [49,50];
Bhlhb2, which is involved in the regulation of lipogen-
esis in liver [51]; and Hmbox1, whose expression levels
was shown to be reduced in liver cancer compared with
surrounding normal tissues [52]. Overall, our predicted
set of liver regulators is comprehensive, spanning sev-
eral different classes of liver related activities including
glucose and lipid metabolism and cancer, and including
both repressors and activators. In addition, Table 1B and
C presents the top 5 predicted TFs for two more tissues
(retina and B cell, p < 10−100 for all, binomial test). As
can be seen, for almost all of these TFs there is strong
support for their tissue-specific activity in the predicted
tissue.
Discussion
A number of recent projects including ENCODE [53],
modENCODE [54,55] and the Roadmap Epigenomics
Project [56] have generated large amounts of genomic
data. An important research goal is to translate these
resources into accurate, tissue and condition-sensitive,
molecular-level networks. Constructing tissue-specific
Table 1 Top five predicted TFs for liver, retina and B cell
TF Score Known functions in the corresponding tissue
A. Liver
Hnf4a 2.22 Essential for maintaining hepatic gene expression
and lipid homeostasis [41]
Rara 1.90 Important in maintaining liver homeostasis, and its
disruption is linked to hepatocarcinogenesis [57]
Nr2f2 1.56 Expressed in liver, and known to regulate liver-
specific genes [58]
Rxra 1.45 Important role in liver metabolism [59]
Tcf7 1.44 Downstream regulator in Wnt signaling which is
critical in liver physiology and pathology [60]
B. Retina
Crx 4.28 Regulates photoreceptor gene expression [40]
Pitx3 4.26 Required for normal retina formation in Xenopus
and zebrafish [61,62]
E2F3 4.06 Involved in retina progenitor cell development [63]
Pitx2 3.92 Pitx2-deficient mouse exhibits ocular
abnormalities [64]
Gsc 3.89 Unknown function in retina.
C. CD19+ B cell
Sfpi1 2.09 Essential regulator of B-cell differentiation [65]
Pou2f2 2.08 Required for T-cell independent B cell activation [66]
Spic 1.98 Promotes B cell differentiation [67]
Pou2f3 1.94 Unknown function in B cell, but has almost the same
binding preference as Pou2f2
Elf4 1.70 Regulates proliferation of B cells [68]
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maps of TF binding sites is a central part of this over-
all research effort. Using several different datasets and
a novel computational strategy, PIPES, we demonstrated
that such high-quality computational predictions can be
obtained. We used PIPES to compile a resource that
includes comprehensive predictions for more than 200
TFs across 50 tissues.
A recent benchmark study that compared many meth-
ods for analyzing PBM data concluded that PWM-based
methods work as well as other models for predicting TFBS
[69]. Our results differ from these previous studies. This
could either be the result of the Lasso based method
we have used or the specific dataset we used for the
comparison. Additional work is required to reach a defini-
tive conclusion regarding the importance of independence
assumption used by PWMs when modeling TFBS. Here
we focused on integrating a number of datasets for pre-
dicting TFBSs. For our biophysical approach, using a
k-mer based method allowed us to capture both the
dependency among positions within the binding site as
well as multiple different motifs for a single TF. Such
method worked well in classifying bound and unbound
sequences from in vivo ChIP-seq data for many TFs.
Moreover, integrating PBM data with chromatin accessi-
bility from DNase I HS data greatly improves the accuracy
of TF binding predictions. Several recent papers explored
related ideas. Chromia [70] used a hidden Markov model
to combine sequence-specific TF binding with histone
modification data, but their predictions were based on
PWM scoring and only focused on a dozen of TFs in
mouse embryonic stem cells. Ernst et al. [23] combined
experimental data from a number of tissues to gener-
ate a single (global) TF-target prediction map. However,
that method has also relied on PWMs and no tissue
specific predictions were made. CENTIPEDE [24] used
unsupervised methods to integrate TF-DNA interaction,
epigenetic and evolutionary data, and is most similar to
our efforts. However, CENTIPEDE relies on a footprint
in the DNase data that TFs leave. Such DNase footprints
are the actual locations where the TF binds and are there-
fore protected from DNase cleavage within the DNase HS
site. Unfortunately, DNase footprint data is expensive to
obtain (indeed, it was not available for most of the tis-
sues we analyzed) since it requires very high coverage
when sequencing. In addition, CENTIPEDE uses a strin-
gent cutoff (based on PWM matching) to define putative
binding sites, and thus may lose significant information
in relatively weak binding sites, which have been shown
to be collectively important for TF binding [71]. Neph
et al. [26,72] also combined DNase footprints with PWMs
to predict TF-TF interactions (though not TF-gene inter-
actions) across a large number of human tissues, using a
simple method to intersect motif matches with DHS sites.
Such hard cutoffs may miss sites that score high (but just
below the cutoff ) for both types of data which are found
by our method.
In general, we find that binding sites for the TFs
we looked at are only modestly conserved when com-
pared with controls (using PhastCons scores alone clas-
sifies ChIP-seq sequences quite poorly, see Additional
file 4). This is largely consistent with the recent find-
ings that functional non-coding sequences evolve rather
rapidly [9]. As a result, adding PhastCons in the inte-
grated model does not lead to improvements in AUC
values. Nevertheless, there are a number of advantages
for models that can incorporate sequence conserva-
tion. First, when DNase data is not available, adding
conservation in the model leads to slight improve-
ment over models that only use PBM data (Additional
file 4). Second, the conservation of binding events can
vary greatly among tissues. For example, enhancers in
brain are far more constrained than those in the heart
[73]. Thus it is quite possible that sequence conser-
vation would be more informative for other ChIP-seq
studies.
The application of PIPES to predict tissue specific TFBS
led to results that agree well with existing knowledge
regarding TF roles in specific tissues. The overall results
are significantly correlated with independent gene expres-
sion data measured for these TFs across tissues even
though such expression data was not used at all in our
analysis.
Several extensions of our current work are possible.
Recently Jiang et al. [74] reported the interesting phe-
nomenon of sticky k-mers: these are k-mers that appear
to bind to TFs with relatively high affinities in a large
number of PBM experiments. The sticky k-mers likely
represent background noises in the PBM experiments and
an interesting research direction is to expand our regres-
sion method to remove such noises. In another recent
study, Ballare et al. [75] reported that functional TFBSs
are not always associated with high chromatin accessibil-
ity, an assumption implicitly made by us and other related
methods. Rather, nucleosomesmay occupy TFBSs at basal
conditions, and are only remodeled or displaced upon
change of cellular conditions (e.g. by hormone stimula-
tion). Despite this unexpected relationship between TFBS
and chromatin states, the paper does report that such
sites, while associated with high nucleosome occupancy
before stimulation, often overlap with DNase HS sites.
It remains to be seen how common such cases are and
what is the impact on methods such as ours that rely
on DNase data to predict condition specific TF bind-
ing. Moreover, our integrative framework for utilizing
additional information sources when predicting binding
events on a genome wide scale could also be used for
large scale comparison of different PWM methods and
methods that use more complicated models to represent
Zhong et al. BMC Genomics 2013, 14:796 Page 9 of 14
http://www.biomedcentral.com/1471-2164/14/796
TF binding preferences [76-78]. This requires a detailed
study and is left for future work.
Conclusions
Combining PBM and DNase data, we presented the first
major effort to provide a systematic map of computation-
ally predicted tissue-specific targets for hundreds of TFs
across a large number of tissues in mouse. We complied
a resource that provides TF-target predictions for all 284
TFs studied across the 55 tissue/cell types (Supplementary
Methods and SupplementaryWebsite in Additional file 4).
We believe that such comprehensive resource would
be useful for both biology and computation-oriented
researchers studying gene regulation [79-82].
Methods
K-mer basedmethod that uses PBM data to predict TF
binding
The binding specificities of TFs are often represented by
position weightmatrices, which assume that each position
of a site contributes independently to the overall bind-
ing affinity of the site (independence assumption). The
PBM data simultaneously measures binding of a TF to
tens of thousands of probes, and can be used to construct
a much more detailed and accurate model of TF binding
specificities.
A biophysically-motivatedmodel for PBM data
Our k-mer based PBM model (Figure 1a) is motivated by
the biophysics of TF binding to the probes in PBM exper-
iments. Following Zhao et al. [16], we denote by Yi the
experimentally measured intensity of the i-th probe on
the PBM array. We denote by F(i) the (unobserved) bind-
ing probability of the TF to this probe. While these two
quantities are related, due to experimental errors and scal-
ing they are not identical. We thus assume a simple linear
model for the mapping between the two:
Yi = a + cF(i) + i (1)
where a and c are constants, and i is the error term. Since
each probe is much longer than the motif itself (probe
length is 36bp while motifs are generally less than 20bp
with a typical length at 12bp [83]) we follow BEEML-PBM
[16], and express the binding probability F(i) as the sum of
the binding probabilities over all k-mers in the probe. Let
k be the length of a TF binding site and L be the length of




λj · βSi(j) (2)
where λj is the position effect at position j (see Supple-
mentary Methods in Additional file 1) and βSi(j) is the
binding probability to Si(j), the k-mer at the j-th position
of the i-th probe. The term βs is symmetric for any k-mer
s, i.e. βs = βs¯, where s¯ is the reverse complement of s.
We note that our model allows features/k-mers to overlap,
so the k-mers can be of different lengths and can contain
gaps. The model relies on Lasso regression to estimate the
contribution of each k-mer (see below).
By plugging in the equation of F(i) into the linear model,
we can couple the different values we obtain for probe
intensities as a function of the individual k-mer contribu-
tions, see Supplementary Methods in Additional file 1 for
full details.
Learning the parameters of the linearmodel
The above linear model has approximately 4k/2 parame-
ters (one for each k-mer and its reverse complement). To
avoid overfitting, we use the lasso regression [84] to esti-
mate the coefficients. Lasso is a widely used approach to
linear regression that encourages a sparse model where
most of the coefficients are zero. In our problem, we
have the additional requirement that the coefficients must
be non-negative, and this is known as positive lasso
[84] (Supplementary Methods in Additional file 1). After
learning the model parameters using positive lasso, we set
β ′s = βs/maxs βs to be the binding probability of the TF to
the k-mer s up to a scaling constant.
Since we do not know the width of the motif bound
by each TF, our method searches for k-mers of different
lengths. In order to speed up the calculation, we first run
positive lasso using all short 4–6 mers. To allow longer k-
mers to be considered, after the first run, all pairs from
the top 100 such k-mers (based on regression coefficients)
are tested to see if the prefix of one matches the suffix
of the other, yielding longer (k + 1)-mers. This process is
repeated until up to 8-mers have been added to the fea-
ture set. In addition, we also allow for gapped k-mers to be
considered (Supplementary methods in Additional file 1).
Predicting TF binding to any sequences
Our model is trained on sequences of 36bp in length (the
length of the variable region of probes in PBM experi-
ments), however, in practice, we often need to predict TF
binding to longer sequences, e.g. promoter regions up to
thousands of base pairs long. Searching for binding sites
in long sequences often involves sliding windows with rel-
ative small size so that signals are not diluted over long
regions. For simplicity, we use 36bp as our window size;
otherwise, additional normalization would be needed for
the PBM scores trained from 36bp probes. To predict
the binding of a TF to a longer sequence (Figure 1b), we
first define the binding probabilities of the TF to each
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in which βs is the binding probability to the k-mer s
learned by the regression model, Cs is the number of
times that s occurs in this site, and Bmax is the high-
est possible unscaled binding probability of any 36-mer
that can be achieved for the TF and is used as a scaling
constant. The interpretation of this equation is that the
binding probability to a 36bp sequence is the sum of bind-
ing probabilities to each of the k-mer of the 36bp sequence
[85,86]. In practice, Bmax is estimated, for each TF, from
the highest unscaled binding probabilities to 100,000 ran-
domly sampled 36bp sites. Then, the binding probability
to the entire sequence is defined as the highest binding
probability to any 36bp site in that sequence.
Integrated model of TF binding in vivo
PBM experiments measure TF binding in vitro. In vivo
binding depends on several factors including the cellular
environment and the chromatin state of the bound region.
In addition, it has been shown that functional TFBSs tend
to be evolutionary constrained [33,34]. In this section, we
describe PIPES, a method that integrates our PBM motif
learning and scanning method with these additional data
sources in order to determine tissue specific binding.
Incorporating DNase I hypersensitivity data
Let Bi be the probability of binding of the TF of inter-
est to a 36bp genomic region (a site) indexed by i based
on the PBM model (Equation 3), reflecting the potential
of TF binding in vitro. We are interested in the in vivo
occupancy of the site, denoted as Xi. We assume that Xi
is influenced by the chromatin state, which can be repre-
sented as a simple binary indicator variable, Ai (it is 1 if
the chromatin is open/accessible and 0 otherwise). When
the chromatin is open (Ai = 1), the occupancy Xi equals
Bi; whereas a closed chromatin at that location means that
Xi = 0. Thus, Xi is simply the product of Bi and P(Ai = 1).
The chromatin state variable can be partially determined
using experimental data. Here we use DNase I hypersen-
sitivity (HS) data (Figure 1c) which is available for several
mouse and human tissues (Results). See Supplementary
Methods in Additional file 1 for details.
The full integratedmodel
To further incorporate the conservation data into PIPES
(Figure 1e), we consider the following graphical model:
Xi ← Zi → Ci → Si (4)
Here Xi is the occupancy of site i as described above,
Zi is a binary variable indicating whether site i is a true
binding site in vivo or not, Ci is a binary variable indi-
cating whether site i is conserved or not, and Si is a
measure of the evolutionary conservation of the site.
The model assumes that true TFBSs have a higher occu-
pancy. Similarly, when Zi = 1, Ci is more likely to be
1 as well (a true binding site is more likely to be con-
served), and this is reflected by a higher conservation
score Si. The goal is to infer Zi from the observed data
Xi and Si. The evolutionary conservation measure we
used is the phastCons score [35] (phastCons 46way verte-
brates) downloaded from the the UCSC Genome Browser
(http://genome.ucsc.edu).
In Supplementary Methods in Additional file 1 we dis-
cuss the specific distributions we assume for each of the
conditional probabilities in our model and how we learn
the parameters for these distributions. After these param-
eters are estimated, we can compute the probability that
the i-th site is bound by a specific TF. See Supplement for
details.
Identifying tissue-specific TF activities
We used PIPES to identify TFs likely to be active in each
tissue. Intuitively, if a TF f is active in a tissue T, then
the binding sites of f should be overrepresented in the
open chromatin regions of T. To quantify this overrep-
resentation, we define R(f ,T) as the fraction of DNase
hypersensitive sites in tissue T that contain high-scoring
binding sites of f. The high scoring sites are defined as
those that have binding probabilities (according to the
PBM model, as defined in Equation 3) higher than the
top 0.1% of the binding probabilities for all possible sites
for that TF (the exact percentage cutoff has little impact,
data not shown). In practice the binding probability dis-
tribution of a TF is estimated from the 100,000 sampled
sites. For each tissue, the open sites in the promoter
regions are defined as those sites whose DNase tag den-
sities are higher than 15. This threshold is chosen so that
the inferred probability of chromatin being open is close
to 1 according to our model. In order to identify TFs hav-
ing active functions in specific cell types, we exclude the
binding sites that are not tissue specific (defined as open in
more than 1/3 of all tissues). Such broadly-active sites are
not interesting for the purpose of finding tissue-specific
TFs.
The activity score of a TF f in tissue T is defined as:
Activity ( f ,T ) = R( f ,T )
R( f , T¯ )
(5)
where T¯ denotes all tissues other than T. This is used as
a measure of the likely activity of the TF in that tissue.
We use a simple binomial test to evaluate the significance
of the activity score defined here. Suppose we observe n
high-scoring binding sites of the TF f in the tissue, and
among these n sites, x sites fall into DNase hypersensitive
regions. By chance, the expected fraction of binding sites
in the DNase HS regions is p = R(f , T¯), thus we perform
the one-sided binomial test of x successes in n trials under
the null model that the probability of success is equal to p.
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A comprehensive collection of predicted TFBSs across 55
mouse tissues
PBM data for 284 mouse TFs were downloaded from
UniPROBE [27]. DNase data for 55 mouse tissue/cell
types were downloaded from the mouse ENCODE
website at http://hgdownload.cse.ucsc.edu/goldenPath/
mm9/encodeDCC/wgEncodeUwDnase/, and for each tis-
sue/cell type, parameters were learned as described in
Methods. A list of all the TFs and tissue/cell types is pro-
vided in Additional files 7 and 8. To predict targets of TFs,
the promoter regions (+/- 10kb around transcription start
sites) for all mouse genes were scanned. This choice of
promoter regions is consistent with several recent publi-
cations [23,70]. We assessed the quality of our predictions
in two ways. (1) The false discovery rates of top TF/tissue
combinations were assessed, and in all but one of 25 com-
binations we examined, the FDR is below 15%. (2) For each
of the 11 TFs we evaluated in the Results, we compared the
set of predicted targeted genes from our method with the
genome-wide targeted genes from the mouse ENCODE
ChIP-seq datasets. The overlap of the two sets are highly
significant for almost all TFs. See Supplementary Meth-
ods and Results in Additional file 1, Additional files 9, 10
and Supplementary Website for details.
Comparison with other methods
To evaluate our methods we obtained ChIP-seq data for
11 TFs for which PBM data and tissue specific DNase
I hypersensitivity data were available (Additional file 2).
ChIP-seq data was downloaded from NCBI GEO or
ENCODE using the GEO IDs or UCSC Accession IDs
listed in Additional file 2.
We performed a comprehensive comparison of our
PBM model with several other methods that could be
or have been used in predicting TF binding on real
sequences. Since most prior methods relied on PWMs,
we used the PWMs reported in UniPROBE [27] for
these TFs, which were obtained by applying the Seed-
and-Wobble algorithm on the PBM data (S&W PWM)
[11]. We also compared with BEEML [16] using both the
energy matrices (BEEML Energy) and converted PWMs
(BEEML PWMs), PWMs identified by RAP (RAP PWMs)
[87], the max E-score of k-mers (Max E-score) [11],
the use of occupancy score proposed by [12], a support
vector regression-based method (SVR) [88], and Featur-
eREDUCE (unpublished). In addition, we also compared
using PWMs from external sources including the JASPAR
database [89] and PWMs derived from HOMER on ChIP-
seq data [31]. Moreover, we also compared our integrative
model with an intersection strategy that combines PWM
scanning with DNase data [72] across multiple tissues, a
simple method that combines PWM scanning with our
DNase model, and an integrative method CENTIPEDE
[24] that uses PWMs, DNase HS and conservation data. A
description of the details for the settings of all methods is
provided in Supplementary Methods in Additional file 1.
Availability of supporting data
The genome-wide tissue-specific TFBS predictions for
284 mouse TFs and 55 tissue/cell types and codes for the
k-mer based PBMmodelingmethod are available from the
supporting website at http://www.sb.cs.cmu.edu/PIPES.
Additional files
Additional file 1: Supplementary methods, results and figures. This
file contains Supplementary Methods, Results and Figures.
Additional file 2: List of TF and ChIP-seq experiments used in
evaluation. This file contains a list of information about the 11 TFs and
corresponding ChIP-seq experiments used in the evaluation.
Additional file 3: Detailed AUCs of different methods using
alternative negative sequence sets and backgroundmodels
(PWM-basedmethods). This file lists the detailed AUCs for methods using
PBM data alone, obtained when alternative negative sequence sets or
background models are used. See Supplementary Methods in Additional
file 1 for details.
Additional file 4: Details of the AUCs for comparing different
methods that predict in vivo TF binding. This file contains the AUCs of
different methods that classify the positive and negative sequences from
ChIP-seq experiments. Methods based on PBM data alone include S&W
PWMs, BEEML PWMs, BEEML Energy, RAP PWMs, Max E-score, Occupancy
score, SVR, FeatureREDUCE and our method. Methods that use external
PWMs include JASPAR PWMs and HOMER PWMs. Methods based on
integrative modeling that also use DNase and phastCons data include our
integrative models (without and with phastCons data), baselines for our
integrative models (DNase alone, phastCons alone and PBM+phastCons),
simple overlapping primary S&W PWMmatches with DNase, combining
S&W, RAP or JASPAR PWMs with our DNase models, and CENTIPEDE under
different settings. See text and Additional file 1 for details.
Additional file 5: Full list of the predicted tissue-specific activity
score for all TFs and tissues. This file lists the predicted activity scores and
binomial test p-values for all the 284 TFs across the 55 cell/tissue types.
Additional file 6: List of TFs and tissues with mRNAmeasurement
data available from [43]. This file lists the TFs and tissues that have mRNA
expression data for the corresponding TF available.
Additional file 7: List of all 55 tissues studied. This file lists the 55
mouse tissue/cell types studied. DNase I hypersensitivity data for these
tissues were downloaded from the UCSC Genome Browser.
Additional file 8: List of all 284 TFs in mouse with PBM data studied.
This file lists the 284 TFs in mouse studied with PBM data available.
Additional file 9: Overlap of genome-wide predictions with ChIP-seq
data at gene level. This file provides the number of overlapping genes in
the genome-wide predictions with ChIP-seq data for the 11 TF/tissues
used in the evaluations. See Supplementary Methods and Results in
Additional file 1 for details.
Additional file 10: FDR estimates. This file provides the estimated false
discovery rates for the genome-wide predictions of the 11 TF/tissues used
in the evaluation and the 15 TF/tissues with highest activity scores. See
Supplementary Methods and Results in Additional file 1 for details.
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